Nadolol

證據等級: L5

預測適應症: 5 個

Nadolol: From Antihypertensive Therapy to Malignant Hypertensive Renal Disease

One-Sentence Summary

Nadolol is a non-selective β-adrenergic blocker whose formal original-indication and mechanism-of-action records are not yet populated in this evidence pack (flagged as data gaps DG001/DG002). The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, but this direction is currently supported only by class-level pharmacological reasoning — 0 clinical trials and 0 publications have been identified for this specific drug–disease pair.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack — DrugBank/TFDA package-insert extraction is an open data gap (DG001 Blocking, DG002 High)
Predicted New Indication	Malignant Hypertensive Renal Disease
TxGNN Prediction Score	99.59%
Evidence Level	L4 (mechanism/class-effect reasoning only)
New Zealand Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data for nadolol has not been extracted into this evidence pack (DG002). Based on the pharmacological class information available in the underlying rationale, nadolol is a non-selective β-blocker, and drugs in this class are known to suppress renin release by blocking β1 receptors on the juxtaglomerular apparatus (JGA). This is a well-established, class-level (not nadolol-specific) mechanism relevant to renin-dependent hypertensive states.

Malignant hypertensive renal disease is typically driven by severe, renin-angiotensin-aldosterone system (RAAS)-dependent hypertension causing renal microvascular injury. Because β-blockade at the JGA can reduce renin secretion, there is a plausible theoretical rationale for a non-selective β-blocker like nadolol to serve as adjunctive antihypertensive therapy in this setting. However, this reasoning is explicitly a class-effect inference, not evidence derived from nadolol itself — no nadolol-specific trial or publication currently supports this pairing, and standard-of-care for malignant hypertension/malignant hypertensive renal disease is generally built around ACE inhibitors/ARBs and rapid blood-pressure control rather than β-blockade as a primary agent.

A closely related, near-identical prediction (rank 2, "malignant renovascular hypertension," score 99.59%) shares the same mechanistic basis and the same evidentiary gap, reinforcing that this is a class-level signal rather than an nadolol-specific finding.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

New Zealand Market Information

Nadolol is currently not marketed in New Zealand and has 0 active authorizations on record. No product license entries are available to summarize in this section.

Other TxGNN-Predicted Indications Screened

For completeness, four additional candidates from the same prediction run were reviewed. None met the bar for prioritization above the primary candidate:

Rank	Predicted Indication	Score	Evidence Level	Decision	Why Held
2	Malignant renovascular hypertension	99.59%	L4	Hold	Same JGA/renin mechanism as rank 1; no nadolol-specific evidence; renovascular hypertension is primarily managed by revascularization or ACEI/ARB, with β-blockade only adjunctive
3	Pulmonary hypertension with unclear multifactorial mechanism	99.53%	L5	Hold	No supporting evidence found; non-selective β-blockers are traditionally used cautiously (relatively contraindicated) in pulmonary arterial hypertension due to negative inotropic/chronotropic effects reducing right-heart compensation — risk plausibly exceeds benefit
4	Pulmonary hypertension owing to lung disease and/or hypoxia	99.53%	L5	Hold	20 PubMed hits were retrieved by keyword ("hypoxia") but on review concern general hypoxia biology (brain aging, oncology, HIF-1α pathways) with no connection to nadolol or β-blocker therapy — this is a keyword-matching artifact, not real evidence. Additionally, non-selective β-blockade carries a theoretical bronchoconstriction risk (β2 blockade) in hypoxic/obstructive lung disease patients
5	Braddock syndrome	99.43%	L5	Hold	Ultra-rare congenital disorder with no known pathophysiological link to β-adrenergic blockade; no trials, no literature — likely a knowledge-graph embedding artifact rather than a real signal

These are reported for transparency but are not recommended for further evaluation at this time.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA/regulatory package-insert warnings and contraindications (DG001) are flagged as a Blocking data gap — this evidence pack cannot yet support even an initial (S1) safety screen for nadolol.

Conclusion and Next Steps

Decision: Hold

Rationale: The leading prediction (malignant hypertensive renal disease) is supported only by a plausible but generic β-blocker class-effect mechanism, with zero nadolol-specific clinical trials or publications identified. Combined with a Blocking data gap on TFDA package-insert warnings/contraindications — which prevents even a baseline (S1) safety assessment — and the drug's non-marketed status in New Zealand, there is currently insufficient evidence or regulatory footing to advance beyond a research hypothesis.

To proceed, the following is needed:

TFDA package-insert data (warnings, contraindications) — resolve Blocking gap DG001 before any safety screening can begin
Confirmed mechanism-of-action and original-indication data from DrugBank — resolve High-severity gap DG002
Nadolol-specific preclinical or clinical evidence (trials or literature) directly addressing malignant hypertensive renal disease, rather than class-level β-blocker inference
Route-of-administration compatibility assessment (currently marked "pending" for all candidate indications)
Clarification of New Zealand regulatory pathway, given the drug is not currently marketed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.